FeesSafety
Pluang+

Inhibrx advances cancer drugs with FDA review for ozekibart due by April 2027

Market News
09 Sep 2026, 15:10 WIB
Seeking Alpha
View Source
Bullish
Inhibrx advances cancer drugs with FDA review for ozekibart due by April 2027

Inhibrx is progressing its cancer treatments ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets. Ozekibart showed a 52% risk reduction in chondrosarcoma progression and strong responses in colorectal and Ewing sarcoma, leading to previous stock gains. INBRX-106 combined with Keytruda demonstrated promising results in head and neck cancer, especially in HPV+ patients. The FDA will decide on ozekibart's Biologics License Application by April 2027, with Inhibrx expanding Phase 2 trials for INBRX-106 aiming for accelerated approval in a $4 billion HPV+ head and neck cancer market and broader immunogenic tumor opportunities worth over $50 billion.

More News

Monday.com expands AI platform; Okta leads in identity security with strong 2026 results.

Monday.com expands AI platform; Okta leads in identity security with strong 2026 results.

Monday.com is growing its AI-driven platform beyond work management into CRM and software development, achieving 22.4% revenue growth and nearly $1.4 billion in revenue for the year ending September 2026. Okta, a leader in identity security, serves o...

Market News
Neutral
50 minutes ago
Invest long-term and avoid market timing to maximize returns, inspired by Wayne Gretzky's advice.

Invest long-term and avoid market timing to maximize returns, inspired by Wayne Gretzky's advice.

Warren Buffett highlights Wayne Gretzky's famous advice, "Skate to where the puck is going to be," as a key investing lesson: focus on the future and stay invested long-term. Fidelity research shows missing the five best days in the S&P 500 from 1987...

Market News
Bullish
1 hour ago
New AI tool checks stock filings for hidden warning signs to aid investors' decisions.

New AI tool checks stock filings for hidden warning signs to aid investors' decisions.

A new AI-powered prompt helps investors identify warning signs in company filings by scanning for issues like auditor doubts, insider sales, and leadership changes. It highlights items worth closer inspection without giving investment advice, using r...

Market News
Bearish
1 hour ago
Netflix's stock drops nearly 47% but remains profitable with growth potential over five years.

Netflix's stock drops nearly 47% but remains profitable with growth potential over five years.

Netflix's shares have fallen nearly 47% from their 52-week high, reflecting concerns about slowing revenue growth and increased competition. Despite this, Netflix remains highly profitable, with rising operating margins and expected revenue growth of...

Market News
Neutral
1 hour ago
Tesla ends Cybertruck production, boosting Rivian's chance to capture electric truck buyers.

Tesla ends Cybertruck production, boosting Rivian's chance to capture electric truck buyers.

Tesla is ending production of its Cybertruck to focus on other projects, leading to increased demand for alternative electric trucks. Rivian, with its newly launched lower-cost R2 model, is well-positioned to attract former Cybertruck customers. This...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App